Vertex Pharmaceuticals
VRTX
976 hedge funds and large institutions have $46.7B invested in Vertex Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 113 funds opening new positions, 397 increasing their positions, 335 reducing their positions, and 125 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 397 | Existing positions reduced: 335
6% more call options, than puts
Call options by funds: $757M | Put options by funds: $713M
0.99% less ownership
Funds ownership: 91.05% → 90.06% (-0.99%)
10% less first-time investments, than exits
New positions opened: 113 | Existing positions closed: 125
2% less funds holding
Funds holding: 999 → 976 (-23)
6% less funds holding in top 10
Funds holding in top 10: 16 → 15 (-1)
8% less capital invested
Capital invested by funds: $50.7B → $46.7B (-$3.95B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$429M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$307M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$284M |
| 4 |
JP Morgan Chase
New York
|
+$258M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$172M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$907M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$722M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$312M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$310M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$278M |
VRTX Hedge Fund Activity: Q2 2021 in Review
976 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2021, worth a combined $46.7B — down 7.8% from $50.7B a quarter earlier.
Sellers outnumbered buyers: 125 funds closed out of VRTX and 113 opened new positions — a net loss of 12 holders — while 335 trimmed existing stakes and 397 added.
The largest buyer was Loomis, Sayles & Company, adding an estimated $429M. The largest seller was Fidelity Investments, cutting an estimated $907M.
- 976 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2021, down from 999 in Q1 2021.
- Funds reported $46.7B of Vertex Pharmaceuticals stock for Q2 2021, down 7.8% quarter-over-quarter.
- 113 funds opened new Vertex Pharmaceuticals positions in Q2 2021 and 125 closed out, a net change of -12 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2021 was Loomis, Sayles & Company, an estimated $429M added.
- The largest Vertex Pharmaceuticals seller in Q2 2021 was Fidelity Investments, an estimated $907M sold.
Based on aggregated 13F filings for Q2 2021.